Cory berkland
Foothold Labs is working with Dr. Cory Berkland of with the University of Kansas Bioengineering & Pharmaceutical Chemistry Departments to explore the capabilities of electrochemical biosensing for pharmaceutical drug research and development purposes. Engenious Design . Engenious Design is a leading product development and engineering firm ...Introduction. Hollow particles, also referred to as capsules or vesicles, are generating interest in industry as well as scientific research. Many active ingredients have been formulated within a capsule core to protect them from the surrounding environment and/or to facilitate sustained release including; adhesives, agrochemicals, catalysts, living cells, flavor oils, pharmaceuticals ...
Did you know?
GI/ORAL. Citation: Dormer N, Berkland C, "Single-Step Functional Coatings for Increased Efficiencies". ONdrugDelivery Magazine, Issue 77 (Jul 2017), pp 28-31. In this article about oral drug innovation, Cory Berkland and Nathan Dormer focus on how enterics and reverse enterics are applied into dosage forms, and discuss the future of this ...Charles Allen Thomas Professor of Chemistry, Chair and Professor of Chemistry. John . HeemstraCory Berkland; Iron overload is a critical clinical condition that can be controlled by diet and the use of iron-specific chelating agents. An effective oral formulation of an iron chelator should ...Qun Wang *, Zhen Gu, Syed Jamal, Michael S. Detamore and Cory Berkland. Hybrid Hydroxyapatite Nanoparticle Colloidal Gels are Injectable Fillers for Bone Tissue Engineering. Tissue Engineering Part A 2013, 19(23-24): 2586-2593. 22. Zhen Gu, Alex Aimetti, Qun Wang, Tram Dang, Yunlong Zhang, Omid Veiseh, Hao Cheng, Robert Langer, Daniel Anderson.Qun Wang, Jinxi Wang, Qinghua Lu, Michael S. Detamoreand Cory Berkland. Injectable PLGA based Colloidal Gels for Zero-order Dexamethasone Release in Cranial Defects. Biomaterials 2010, 31(18): 4980-4986. 17. Qun Wang, Xianwen Hu, Yumin Du and John F. Kennedy. Alginate/Starch Blend Fibers and Their Properties for Drug Controlled Release.Brittany L. Hartwell, 1 Chad J. Pickens, 2 Martin Leon, 3 Laura Northrup, 2 Matthew Christopher, 2 J. Daniel Griffin, 1 Francisco Martinez-Becerra, 4 and Cory Berkland 1, 2, 5, * Brittany L. Hartwell 1 Bioengineering Graduate Program, University of Kansas 1520 West 15 th Street, Lawrence, KS 66045, USA Ruolin Lu, 1 Chad Groer, 2 Peter A. Kleindl, 1 K. Ryan Moulder, 1 Aric Huang, 1 Jordan R. Hunt, 1 Shuang Cai, 1, 2 Daniel J. Aires, 2, 3 Cory Berkland, 1 and Laird Forrest 1, 2, * Ruolin Lu 1 Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KansasCalcium-crosslinked LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells Supang Khondee1, Abdulgader Baoum1, Teruna J. Siahaan1, and Cory Berkland1,2,* 1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047 2Department of Chemical and Petroleum Engineering, The University of Kansas, Lawrence, KSKhia Preston Director Of Operations at The UPS Store - #3263, 2473, 3354, 3723, 1152, 3443, 0754As an alternative, nanoparticles may be targeted to a specific tissue with up-regulated cell adhesion molecules such as intercellular cell-adhesion molecule-1 (ICAM-1), which is dramatically up-regulated (~10 fold or more) on the vascular endothelium in response to the increased production of proinflammatory cytokines such as interleukin-1-β ...Corresponding Author. Cory Berkland. [email protected]; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, 66047 USA. E-mail: [email protected]; [email protected] Search for more papers by this authorCory Berkland. Cory Berkland. Solon E. Summerfield Distinguished Professor. Department of Pharmaceutical Chemistry. Contact Info. [email protected] average moduli of the scaffolds, determined from the stress-strain plots using the end of the initial linear regions before the onset of the nonlinear region (the rationale for this will explained later), ranged from 71 to 196 kPa (Fig. 3), which may be suitable for cartilage tissue engineering applications.A higher intrinsic viscosity of the polymer, a decreased average diameter of the ...The aim of this project was to develop a gene replacement therapy for treating Charcot-Marie-Tooth disease type 4C to rescue the phenotype of the Sh3tc2-/- mouse model. We generated a lentiviral vector LV-Mpz.SH3TC2.myc to drive expression of the human SH3TC2 cDNA under the control of the Mpz promoter specifically in myelinating Schwann cells.Todd Berkland Work Experience and Education. According to ZoomInfo records, Todd Berkland`s professional experience began in 2000. Since then Todd has changed 4 companies and 3 roles. Currently, Todd Berkland works as a Vice President, Business Development & Acquisitions at Wrench Group.Corporate Faith - 2023 Business Speakers Series - Cory Berkland. Mon, Aug 14, 6:00 PM. Undivided Experience Center • Chesterfield, MO. Free. Save Corporate Faith - 2023 Business Speakers Series - Cory Berkland to your collection.Cory Berkland Laird Forrest Michael Hageman Jeff Krise Sue Lunte Russ Middaugh Christian Schöneich Teruna Siahaan John Stobaugh Thomas Tolbert David Volkin Michael Wang Undergraduate Research Program ...Cory Berkland (BSChE'98) and Devin Shepard (BSChE'97) will receive the 2013 Professional Progress in Engineering Award from the College of Engineering at the Marston Club Dinner on April 18. The award was created to recognize outstanding professional progress, personal development, and distinguished community service by engineering alumni under the age of 46. Berkland is a professor in the ...Cory Berkland, PhD: Cory Berkland holds the Solon E. Summerfield Distinguished Professorship in the Department of Pharmaceutical Chemistry and in the Department of Chemical Engineering at The University of Kansas.Berkland C, King M, Cox A, Kim K, Pack DW. Precise control of PLG microsphere size provides enhanced control of drug release rate . Journal of Controlled Release . 2002 Jul 18;82(1):137-147. doi: 10.1016/S0168-3659(02)00136-1. INTRODUCTION. Hyaluronic acid (HA) is a linear biopolymer component of multiple approved products and exhibits versatility for drug delivery, since it is available in a wide range of molecular weights and offers multiple sites for chemical modification. 1-6 In the human body, HA is prevalent in cartilage, skin, and synovial fluid and is typically present as a very high molecular weight ...Cory Berkland spun Austin, Texas-based Savara Inc. out of his University of Kansas lab in 2007 to develop aerosolized drug therapies. It's the first company wCory Berkland, PhD President, CEO and Chairman. Dr. Berkland serves as the Chairman of the Board, President, Chief Executive Officer (CEO), and Co-Founder of Bond Biosciences.
Home. Cory Berkland. Distinguished Professor, Pharmaceutical Chemistry. Professor, Chemical & Petroleum Engineering. Contact Info. [email protected]. 785-864-1455. …Qingting Hu, 1 Megan Myers, 1 Wei Fang, 1 Min Yao, 1 Gage Brummer, 1 Justin Hawj, 1 Curtis Smart, 1 Cory Berkland, 2 and Nikki Cheng 1, 3, * Qingting Hu 1 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USACory Berkland Many current therapies for autoimmune diseases such as multiple sclerosis (MS) result in global immunosuppression, rendering insufficient efficacy with increased risk of adverse side ...Cory Berkland is a Professor in the Department of Pharmaceutical Chemistry and in the Department of Chemical Engineering at The University of Kansas. He received MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois in Urbana-Champaign and a BS degree in Chemical Engineering from Iowa ...
Noncovalently associated cell-penetrating peptides for gene delivery applications. 2013 Jun;4 (6):741-57. doi: 10.4155/tde.13.44. Nabil A Alhakamy Adane S Nigatu Cory J Berkland Joshua D Ramsey. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA. 23738670.6 records for Cory Berkland. Find Cory Berkland's phone number, address, and email on Spokeo, the leading online directory for contact information.…
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. OTM Office Hours: Cory Berkland (University of . Possible cause: Cory Berkland. Chemical & Petroleum Engineering, 1530 West 15th St.
The aim of this project was to develop a gene replacement therapy for treating Charcot-Marie-Tooth disease type 4C to rescue the phenotype of the Sh3tc2-/- mouse model. We generated a lentiviral vector LV-Mpz.SH3TC2.myc to drive expression of the human SH3TC2 cDNA under the control of the Mpz promoter specifically in myelinating Schwann cells.Prof. Berkland is a co-founder of Orbis Biosciences, Savara Pharmaceuticals, Bond Biosciences and Orion BioScience. He is also a …
Deanna Diaz, "Utilizing Fluorescent Soluble Antigen Arrays for B Cell Detection," mentored by Cory Berkland, Solon E. Summerfield Distinguished Professor of Pharmacy Connor Dougan , "PERIOD, Period: Student Analysis of the Effectiveness of The University of Kansas' and PERIOD's Free Menstrual Products on Campus," mentored by Ivery ...Teruna, and Berkland Cory* Department of Pharmaceutical Chemistry, School of Pharmacy, The University of Kansas, Lawrence, Kansas, 66047 ... Kansas 66047 Phone: (785) 864-1455 Fax: (785) 864-1454 [email protected]. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our ...J Pharm Innov (2010) 5:70–71 DOI 10.1007/s12247-010-9084-0 EDITORIAL Cory Berkland Published online: 16 July 2010 # Springer Science+Business Media, LLC 2010 In the pharmaceutical community, nanotechnology has that particles with a diameter larger than about 10 nm may become the flavor of the day for anything with a size or …
Abdulgader A. Baoum1 and Cory J. Berkland1,2,* 1Department o The long-term objective of this application is to deliver a unique biomaterial that can easily be molded into place by a surgeon, and will resorb as it induces rapid tissue regeneration. Toward this o...1. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008 May 22; 60(8):915–928. † We reviewed the field of nanotechnology applied to vaccine formulation and delivery in 2008. 2. O’Hagan DT, Fox CB. New generation adjuvants–from empiricism to rational design. Vaccine. 2015 Jun 8; 33(Suppl 2):B14 ... Cory Berkland The University of Kansas Lawrence, KS. Joel Bernstein NeCory Berkland, University of Kansas, Chemical and Cory Berkland, Ph.D.-Solon E. Summerfield Distinguished Professor-Chemical and Petroleum Engineering-Pharmaceutical Chemistry; View full profile . Jonathan Brumberg, Ph.D.-Associate Professor, Speech-Language-Hearing: Sciences & Disorders-Courtesy Associate Professor, Electrical Engineering & Computer Science;Dr. Cory J. Berkland Dr. Donna Pacicca June 17, 2014 Date defended. ii ACCEPTANCE PAGE ACCEPTANCE PAGE The Thesis Committee for Amanda Sutherland certifies that this is the approved version of the following dissertation: Decellularized Cartilage as a Bioactive Biomaterial for Cartilage Tissue ICAM-1 mobility on the cell surface leads to a phe Practical Considerations, Challenges, and Limitations of Bioconjugation via Azide-Alkyne Cycloaddition Chad J. Pickens1, Stephanie N. Johnson1, Melissa M. Pressnall1, Martin A. Leon2, and Cory J. Berkland1,2 1Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047, USACory Berkland, PhD, is the Solon E Summerfield Distinguished Professor at the University of Kansas, US. He is a co-founder and was Chief Scientific Officer of Orbis Biosciences (now Adare Pharmaceuticals) amongst other companies including Savara Pharmaceuticals, Bond Biosciences and Orion BioScience. Professor Berkland has a PhD in Chemical and ... Fang WB, Yao M, Jokar I, Alhakamy N, BerklCo-Founder & Chief Executive Officer at Context Therapeutics.Globalization of Pharmaceutics Education N The induction of immune response by presentation of antigen on or with immune stimulating “signal” is a primary design metric of vaccines. We rationalized that a similar strategy could also be used to design antigen-SITs to induce tolerance to autoantigen. Both approaches focus on the recognition, attack, and removal of a “foreign ... Amir Fakhari1 and Cory Berkland1,2,3,* 1Bioengineeri Cory Berkland, CEO [email protected] Release Summary Bond's clinical lead, BBI-001, is designed to rapidly and selectively bind dietary iron to reduce iron absorption in patients with iron overload.Cory Berkland Solon E. Summerfield Distinguished Professor Department of Pharmaceutical Chemistry Contact Info [email protected] 785-864-1455 Multidisciplinary Research Building, Room 320E 2030 Becker Drive Lawrence, KS 66047 Personal Links Cory Berkland Research Education — Ph.D. in Chemical and Biomolecular Engineering, University of Illinios That effort led to an NIH grant with Cory Berkland, Ph.D.[A polyelectrolyte complex for the controlled release of an oil and gasOTM Office Hours: Cory Berkland (University of Kansas), Heid Acute B-Cell Inhibition by Soluble Antigen Arrays is Valency-Dependent and Predicts Immunomodulation in Splenocytes J. Daniel Griffin1, Martin A. Leon2, Jean R. Salash3, Michael Shao4, Brittany L. Hartwell1, Chad J. Pickens3, Joshua O. Sestak3, Cory Berkland1,3,4 1Bioengineering Graduate Program, University of Kansas, Lawrence, KS 2Department of Chemistry, University of Kansas, Lawrence, KS